title: Characterization of human pre-elafin mutants: full antipeptidase activity is essential to preserve lung tissue integrity in experimental emphysema.
abstract: Pre-elafin is a tight-binding inhibitor of neutrophil elastase and myeloblastin; two enzymes thought to contribute to tissue damage in lung emphysema. Previous studies have established that pre-elafin is also an effective anti-inflammatory molecule. However, it is not clear whether both functions are linked to the antipeptidase activity of pre-elafin. As a first step toward elucidating the structure/function relationship of this protein, we describe here the construction and characterization of pre-elafin variants with attenuated antipeptidase potential. In these mutants, the P1' methionine residue of the inhibitory loop is replaced by either a lysine (pre-elafinM25K) or a glycine (pre-elafinM25G) residue. Both mutated variants are stable and display biochemical properties undistinguishable from WT (wild-type) pre-elafin. However, compared with WT pre-elafin, their inhibitory constants are increased by one to four orders of magnitude toward neutrophil elastase, myeloblastin and pancreatic elastase, depending on the variants and enzymes tested. As suggested by molecular modelling, this attenuated inhibitory potential correlates with decreased van der Waals interactions between the variants and the enzymes S1' subsite. In elastase-induced experimental emphysema in mice, only WT pre-elafin protected against tissue destruction, as assessed by the relative airspace enlargement measured using lung histopathological sections. Pre-elafin and both mutants prevented transient neutrophil alveolitis. However, even the modestly affected pre-elafinM25K mutant, as assayed in vitro with small synthetic substrates, was a poor inhibitor of the neutrophil elastase and myeloblastin elastolytic activity measured with insoluble elastin. We therefore conclude that full antipeptidase activity of pre-elafin is essential to protect against lung tissue lesions in this experimental model.
authors.affiliation: Département de biochimie et de microbiologie, Université Laval, Québec, Qc, Canada.
authors.forename: Alain
authors.initials: A
authors.lastname: Doucet
authors.forename: Dominique
authors.initials: D
authors.lastname: Bouchard
authors.forename: Marie France
authors.initials: MF
authors.lastname: Janelle
authors.forename: Audrey
authors.initials: A
authors.lastname: Bellemare
authors.forename: Stéphane
authors.initials: S
authors.lastname: Gagné
authors.forename: Guy M
authors.initials: GM
authors.lastname: Tremblay
authors.forename: Yves
authors.initials: Y
authors.lastname: Bourbonnais
mesh_terms: D000818:Animals; D053492:Elafin / Q000737:chemistry / Q000235:genetics* / Q000378:metabolism*; D004646:Emphysema / Q000378:metabolism / Q000473:pathology*; D005260:Female; D005786:Gene Expression Regulation; D007700:Kinetics; D008168:Lung / Q000166:cytology / Q000378:metabolism* / Q000473:pathology; D051379:Mice; D008810:Mice, Inbred C57BL; D008958:Models, Molecular; D050505:Mutant Proteins / Q000737:chemistry / Q000235:genetics / Q000378:metabolism*; D009154:Mutation / Q000235:genetics*; D009504:Neutrophils / Q000378:metabolism; D011487:Protein Conformation; D015842:Serine Proteinase Inhibitors / Q000737:chemistry / Q000235:genetics / Q000378:metabolism*
chemical_list: D053492:Elafin; D050505:Mutant Proteins; C506806:PI3 protein, human; D015842:Serine Proteinase Inhibitors